JAZZ PHARMACEUTICALS ($JAZZ) posted quarterly earnings results for Q3 2026 on Monday, November 2nd. The company reported earnings of -$3.88 per share, beating estimates of -$3.93 by $0.05. The company also reported revenue of $1,243,000,000, beating estimates of $1,231,705,559 by $11,294,441.
You can see Quiver Quantitative's $JAZZ stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
JAZZ PHARMACEUTICALS Insider Trading Activity
JAZZ PHARMACEUTICALS insiders have traded $JAZZ stock on the open market 18 times in the past 6 months. Of those trades, 0 have been purchases and 18 have been sales.
Here’s a breakdown of recent trading of $JAZZ stock by insiders over the last 6 months:
- ROBERT IANNONE (EVP, Global Head of R&D & CMO) has made 0 purchases and 6 sales selling 76,921 shares for an estimated $19,207,097.
- BRUCE C COZADD has made 0 purchases and 4 sales selling 24,000 shares for an estimated $5,753,400.
- SAMANTHA PEARCE (EVP, Chief Commercial Officer) sold 6,907 shares for an estimated $1,625,976
- RENEE D GALA (President & CEO) has made 0 purchases and 2 sales selling 4,000 shares for an estimated $958,860.
- RICK E WINNINGHAM sold 2,741 shares for an estimated $662,143
- NEENA M PATIL (EVP & Chief Legal Officer) has made 0 purchases and 2 sales selling 2,392 shares for an estimated $571,596.
- HEATHER ANN MCSHARRY sold 2,000 shares for an estimated $482,000
- MARK DOUGLAS SMITH sold 1,157 shares for an estimated $266,746
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
JAZZ PHARMACEUTICALS Hedge Fund Activity
We have seen 377 institutional investors add shares of JAZZ PHARMACEUTICALS stock to their portfolio, and 251 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 2,333,564 shares (+102.5%) to their portfolio in Q2 2026, for an estimated $562,318,917
- ECOR1 CAPITAL, LLC removed 1,706,469 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $411,207,834
- JPMORGAN CHASE & CO added 1,160,786 shares (+inf%) to their portfolio in Q2 2026, for an estimated $279,714,602
- NORGES BANK added 656,843 shares (+inf%) to their portfolio in Q2 2026, for an estimated $158,279,457
- HOLOCENE ADVISORS, LP removed 572,914 shares (-78.1%) from their portfolio in Q2 2026, for an estimated $138,055,086
- MARINER, LLC added 568,599 shares (+1420.9%) to their portfolio in Q2 2026, for an estimated $137,015,301
- MILLENNIUM MANAGEMENT LLC removed 498,631 shares (-39.5%) from their portfolio in Q2 2026, for an estimated $120,155,112
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
JAZZ PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $JAZZ recently. We have seen 7 analysts offer price targets for $JAZZ in the last 6 months, with a median target of $270.0.
Here are some recent targets:
- Gregg Gilbert from Deutsche Bank set a target price of $270.0 on 07/09/2026
- Gregory Renza from Truist Securities set a target price of $254.0 on 07/07/2026
- Jason Gerberry from B of A Securities set a target price of $307.0 on 06/10/2026
- Etzer Darout from Barclays set a target price of $253.0 on 05/27/2026
- Jeffrey Walch from Bernstein set a target price of $229.0 on 05/22/2026
- David Amsellem from Piper Sandler set a target price of $301.0 on 05/22/2026
- Ashwani Verma from UBS set a target price of $307.0 on 05/19/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
